The American Association of Clinical Endocrinology (AACE) has released its 2025 Consensus Statement and updated algorithm for the management of adults with dyslipidemia, offering concise visual guidance and tables to support clinical decision-making aimed at reducing atherosclerotic cardiovascular disease (ASCVD) and triglyceride-induced pancreatitis risk. Developed by an international multidisciplinary task force, the update builds upon the 2020 AACE algorithm and integrates current evidence and expert consensus. The 2025 algorithm outlines guiding principles for patient-centered management, comprehensive risk assessment, identification of genetic dyslipidemias, lifestyle interventions, LDL-cholesterol–lowering pharmacotherapy, approaches to statin-associated muscle symptoms, and management strategies for hypertriglyceridemia and special populations—including older adults, those receiving transgender care or HIV treatment, and pregnant or lactating individuals. Aligned with the 2025 AACE Clinical Practice Guideline for Pharmacologic Management of Dyslipidemia and consistent with other international guidance, this update emphasizes individualized therapy, ASCVD and pancreatitis risk assessment, and the integration of health equity, cost-effectiveness, and risk–benefit considerations into dyslipidemia management. Source: https://www.endocrinepractice.org/
The American Cancer Society (ACS) concludes that the benefits of PSA-based screening for prostate cancer…
Proton pump inhibitor (PPI) use was modestly associated with incident dementia in older adults (pooled…
Extended follow-up of three major trials consistently shows that an initial invasive strategy does not…
Escitalopram, duloxetine, and agomelatine achieved higher sustained response rates than fluoxetine, while escitalopram and duloxetine…
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
This website uses cookies.